Amedisys, Inc.
AMEDNASDAQHealthcare
$100.99
+$0.01(+0.01%)
Market Cap$3.3B
P/E Ratio—
52W High$101.02
52W Low$82.15
Amedisys, Inc. (AMED) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMED · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Jul 29, 2025EPS Actual
$1.54
Est. $1.39 · +10.8%
Revenue
$0.62B
Est. $0.64B · -2.2%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Jul 29, 2025
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
AMED reports quarterly as a NASDAQ-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Jul 29, 2025 | $1.39 | $1.54 | +10.8% | $0.62B | $0.64B | -2.2% |
| ▲ Q2 FY2025 | Apr 23, 2025 | $1.13 | $1.25 | +10.6% | $0.59B | $0.61B | -2.8% |
| ▼ Q1 FY2025 | Feb 26, 2025 | $1.05 | $0.96 | -8.6% | $0.60B | $0.60B | -0.7% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $1.17 | $1.00 | -14.5% | $0.59B | $0.60B | -1.5% |
| ▲ Q3 FY2024 | Jul 24, 2024 | $1.22 | $1.32 | +8.2% | $0.59B | $0.58B | +2.1% |
| ▲ Q2 FY2024 | Apr 24, 2024 | $1.01 | $1.03 | +2.0% | $0.57B | $0.57B | +1.1% |
| ▼ Q1 FY2024 | Feb 21, 2024 | $1.03 | $0.94 | -8.7% | $0.57B | $0.57B | +0.5% |
| ▼ Q4 FY2023 | Oct 24, 2023 | $1.08 | $0.98 | -9.3% | $0.56B | $0.56B | -0.9% |
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
$1.54
EPS Est.
$1.39
EPS Surpr.
+10.8%
Revenue
$0.62B
Q2 FY2025
Apr 23, 2025Beat
EPS Actual
$1.25
EPS Est.
$1.13
EPS Surpr.
+10.6%
Revenue
$0.59B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
$0.96
EPS Est.
$1.05
EPS Surpr.
-8.6%
Revenue
$0.60B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$1.00
EPS Est.
$1.17
EPS Surpr.
-14.5%
Revenue
$0.59B
Q3 FY2024
Jul 24, 2024Beat
EPS Actual
$1.32
EPS Est.
$1.22
EPS Surpr.
+8.2%
Revenue
$0.59B
Q2 FY2024
Apr 24, 2024Beat
EPS Actual
$1.03
EPS Est.
$1.01
EPS Surpr.
+2.0%
Revenue
$0.57B
Q1 FY2024
Feb 21, 2024Miss
EPS Actual
$0.94
EPS Est.
$1.03
EPS Surpr.
-8.7%
Revenue
$0.57B
Q4 FY2023
Oct 24, 2023Miss
EPS Actual
$0.98
EPS Est.
$1.08
EPS Surpr.
-9.3%
Revenue
$0.56B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.30 | $1.30 | $1.30 | 1 |
| Q3 FY2027 | $1.40 | $1.40 | $1.40 | 1 |
| Q2 FY2027 | $1.42 | $1.42 | $1.42 | 1 |
| Q1 FY2027 | $1.37 | $1.37 | $1.37 | 1 |
| Q4 FY2026 | $1.23 | $1.23 | $1.23 | 1 |
| Q3 FY2026 | $1.23 | $1.23 | $1.23 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.7B | $0.7B | $0.7B | 2 |
| Q3 FY2027 | $0.7B | $0.7B | $0.7B | 2 |
| Q2 FY2027 | $0.7B | $0.7B | $0.7B | 2 |
| Q1 FY2027 | $0.7B | $0.7B | $0.7B | 2 |
| Q4 FY2026 | $0.7B | $0.7B | $0.7B | 2 |
| Q3 FY2026 | $0.6B | $0.6B | $0.6B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Jul 29, 2025 | +10.8% | $96.91 | $97.52 | +0.63% |
| ▲ Q2 FY2025 | Apr 23, 2025 | +10.6% | $92.43 | $93.63 | +1.30% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -8.6% | $91.54 | $91.57 | +0.03% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -14.5% | $95.96 | $97.71 | +1.82% |
| ▲ Q3 FY2024 | Jul 24, 2024 | +8.2% | $97.75 | $97.58 | -0.17% |
| ▲ Q2 FY2024 | Apr 24, 2024 | +2.0% | $91.16 | $91.05 | -0.12% |
| ▼ Q1 FY2024 | Feb 21, 2024 | -8.7% | $93.69 | $93.61 | -0.09% |
| ▼ Q4 FY2023 | Oct 24, 2023 | -9.3% | $92.21 | $92.18 | -0.03% |
Q3 FY2025+0.63%
Report Date
Jul 29, 2025
EPS Beat/Miss
+10.8%
Price Before
$96.91
Price After
$97.52
Q2 FY2025+1.30%
Report Date
Apr 23, 2025
EPS Beat/Miss
+10.6%
Price Before
$92.43
Price After
$93.63
Q1 FY2025+0.03%
Report Date
Feb 26, 2025
EPS Beat/Miss
-8.6%
Price Before
$91.54
Price After
$91.57
Q4 FY2024+1.82%
Report Date
Nov 6, 2024
EPS Beat/Miss
-14.5%
Price Before
$95.96
Price After
$97.71
Q3 FY2024-0.17%
Report Date
Jul 24, 2024
EPS Beat/Miss
+8.2%
Price Before
$97.75
Price After
$97.58
Q2 FY2024-0.12%
Report Date
Apr 24, 2024
EPS Beat/Miss
+2.0%
Price Before
$91.16
Price After
$91.05
Q1 FY2024-0.09%
Report Date
Feb 21, 2024
EPS Beat/Miss
-8.7%
Price Before
$93.69
Price After
$93.61
Q4 FY2023-0.03%
Report Date
Oct 24, 2023
EPS Beat/Miss
-9.3%
Price Before
$92.21
Price After
$92.18
Avg Beat Reaction+0.41%
Avg Miss Reaction+0.43%
Beat Rate4 / 8 quarters
Largest Move+1.82% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMED ends December
Amedisys, Inc. (AMED) most recently reported earnings on July 29, 2025 for Q3 FY2025, posting EPS of $1.54 — beating the analyst consensus of $1.39 by +10.8%. AMED has beaten EPS estimates for 2 consecutive quarters. The next AMED earnings date is expected around September 1, 2026.
Each quarter, investors track AMED earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMED revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMED's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMED earnings · 5 questionsAmedisys, Inc.'s next earnings report is expected around September 1, 2026. AMED typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMED historically reports after market close (AMC).
AMED earnings datewhen is AMED earningsAMED next earnings datewhen does AMED report earningsAMED earnings calendar
▸ Source: FMP · Amedisys, Inc. SEC filings · US GAAP · Amedisys, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026